Submit your Defective Drugs claim details for a free, no obligation case review.
Get Started:
drug_recall crestorThe most serious Crestor risk that has been associated with this prescription drug''s use is the development of a serious muscle condition called Rhabdomyolosis. This Crestor risk has caused the deaths of about 30 patients since this cholesterol drug was first approved for use in the United States. Crestor has been touted as a super statin that effectively lowers cholesterol levels in patients who take this drug. AstraZeneca, Crestor''s maker, who enjoys billions of dollars in revenue from sales of this medication, has yet to acknowledge the serious Crestor risk threats that are associated with the use of their blockbuster drug.
The threat of Crestor risk health problems has been known by the FDA since AstraZeneca first applied for approval to market Crestor in 2001. The FDA found that Crestor risk outweighed the drug''s intended benefits in patients taking doses of 80 milligrams and, in some cases, even 40 milligrams. The Crestor risk posed to these patients included a great chance of suffering muscle problems and serious kidney damage.
Consumer advocacy groups have been outspoken about the serious Crestor risk since this drug was approved for use in the United States. A prominent group called Public Citizen has issued dozens of Crestor risk warnings and has repeatedly urged the federal government to mandate a recall of this dangerous drug. This group cites evidence that the rate of kidney damage is 75 times higher in patients taking Crestor than those taking other cholesterol-reducing medications.
Crestor risk warnings have been underestimated by the manufacturers of this drug who insist that Crestor is no more dangerous than other statin drugs. The fact that at least thirty people have lost their lives as a result of Crestor risk side effects has not led to any changes in the way that this drug is regulated or prescribed.
In addition to the threat of developing a serious muscle disease and kidney or other organ damage, Crestor risk warnings have also been made pertaining to other possible side effects. In pregnant or lactating women, a high Crestor risk is posed to developing fetuses and nursing newborns. Patients who consume grapefruit and grapefruit juice are also at an elevated Crestor risk of suffering serious side effects. Addition Crestor risk warnings have included drug interactions with medications such as Warfarin, Cyclosporine, and Gemfibrozil. Animal studies have found Crestor risk side effects involving central nervous system toxicity.
The most serious Crestor risk is the threat of developing Rhabdomyolosis, which if left undiagnosed and untreated can lead to kidney damage, failure, and even death. Despite public pressure and evidence of serious Crestor risks, the FDA and AstraZeneca have failed to address these problems and take measures to protect patients from Crestor risk threats. If you experience any adverse side effects while taking Crestor, it is important to notify your doctor. To learn more about the serious Crestor risk factors, you may also wish to contact your medical practitioner.
The consumer advocacy group Public Citizen submitted a petition to the FDA a year ago asking the agency to immediately withdraw the anti-cholesterol drug Crestor, but the agency has denied its request.
Crestor belongs to a group of drugs ...
The FDA has announced that Crestor is being relabeled to add a warning that starter doses should be reduced in Asian-American patients, as well as some other higher risk patients.
A clinical trial found that levels in Asian patients were d...
The FDA announced a revised drug labeling for the cholesterol-lowering drug Crestor would be added, warning of the serious muscle damage called rhabdomyolysis.
A clinical trial found levels of Crestor in Asian patients were double those of C...